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BACKGROUND: An elevated preoperative C-reactive protein/albumin (CRP/Alb) ratio has been reported to be
associated with a poor prognosis for hepatocellular carcinoma. The aim of the present study was to investigate the
prognostic value of the preoperative CRP/Alb ratio and compare it with other systemic inflammatory response
markers in patients with gastric cancer (GC).METHODS: A retrospective study was performed in 455 patients with
GC undergoing curative resection. We investigated the correlations between the preoperative CRP/Alb ratio and
overall survival (OS). Kaplan-Meier and Cox regressionmodels were used to assess independent prognostic factors.
The area under the curve was used to compare the prognostic value of different markers. RESULTS:Onmultivariate
analysis, the CRP/Alb ratio were independently associated with OS in patients with GC (hazard ratio: 1.626; 95%
confidence interval: 1.191-2.219; P = .002), along with age (P = .003), preoperative body weight loss (P = .001),
tumor location (P = .008), metastatic lymph node ratio (P b .001), and seventh tumor-nodes-metastasis stage
(American Joint Committee on Cancer) (P= .007). However, several other systemic inflammation–based prognostic
scores (neutrophil lymphocyte ratio, platelet lymphocyte ratio and systemic immune-inflammation index, Glasgow
Prognostic Score, modified Glasgow prognostic score, and high-sensitivity modified Glasgow prognostic score)
were not. In addition, the CRP/Alb ratio had a higher area under the curve value (0.625) compared with several other
systemic inflammation–based prognostic scores (P b .001).CONCLUSION: The preoperative CRP/Alb ratio, a system
inflammation-based prognostic score, is a superior predictor of OS in patients undergoing curative resection for GC
and may help to identify the high-risk patients for treatment decisions.
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Gastric cancer (GC), one of the most common malignant tumors in
the digestive tract, is the second most frequent cause of mortality
worldwide [1]. Over the past couple of decades, although advances
have been seen in surgical techniques and adjuvant chemotherapy, the
prognosis of patients with GC still remains unsatisfactory [2].
Therefore, it is of important significance to identify promising
prognostic factors to select patients for tailor treatment.
It is now increasingly recognized that the systemic inflammatory
response plays an important role in carcinogenesis and tumor
progression [3–5]. A number of studies have demonstrated that the
systemic inflammatory response is associated with a poor prognosis in
various types of cancer. Several common inflammation-basedprognostic scores, including the Glasgow Prognostic Score (GPS),
modified Glasgow prognostic score (mGPS), high-sensitivity modi-
fied Glasgow prognostic score (HS-mGPS), neutrophil lymphocyte
Table 1. Clinical and Laboratory Characteristics of 455 GC Patients Associated with OS
No. of Patients (%) OS (Months) Mean (95% CI) P Value
Patient-related factors
Sex .895
Male 314 (69.0%) 39.8 (36.5-43.0)
Female 141 (31.0%) 40.1 (35.1-45.0)
Age (years) .002
b60 252 (55.4%) 43.9 (40.2-47.5)
≥60 203 (44.6%) 34.9 (31.0-38.8)
Preoperative body weight loss b .001
No 220 (48.4%) 46.3 (42.3-50.3)
Limited 170 (37.4%) 36.8 (32.6-40.9)
Severe 65 (14.3%) 26.6 (20.8-32.5)
BMI (kg/m2) .108
b18.5 71 (15.6%) 32.2 (26.0-38.5)
18.5 ≤ b23.0 223 (49.0%) 41.2 (37.3-45.1)
23.0 ≤ b25.0 90 (19.8%) 40.0 (33.7-46.0)
25.0≤ 71 (15.6%) 42.7 (36.1-49.4)
Neutrophils (×109/L) .002
b7.5 417 (91.6%) 41.1 (38.3-44.0)
≥7.5 38 (8.4%) 26.1 (19.1-33.1)
Lymphocytes (×109/L) .510
b3 431 (94.7%) 40.2 (37.4-43.0)
≥3 24 (5.3%) 34.1 (23.8-44.4)
Platelet (×109/L) .478
b400 416 (91.4%) 40.3 (37.4-43.1)
≥400 39 (8.6%) 35.3 (26.7-43.8)
CRP (mg/L) .002
≤10 388 (85.3%) 41.6 (38.6-44.6)
N10 67 (14.7%) 29.8 (23.8-35.8)
Alb (g/L) b .001
b35 51 (11.2%) 24.2 (18.7-29.8)
≥35 404 (88.8%) 41.7 (38.9-44.6)
NLR b .001
b2.3 269 (59.1%) 44.6 (41.0-48.2)
≥2.3 186 (40.9%) 33.3 (29.4-37.2)
PLR b .001
b180 336 (73.8%) 42.8 (39.6-46.0)
≥180 119 (26.2%) 31.3 (26.6-35.9)
SII .001
b660 302 (66.4%) 43.1 (39.7-46.5)
≥660 153 (33.6%) 33.5 (29.3-37.7)
GPS b .001
0 350 (76.9%) 43.6 (40.5-46.7)
1 92 (20.2%) 26.8 (21.9-31.6)
2 13 (2.9%) 29.9 (19.2-40.5)
mGPS .001
0 274 (60.2%) 44.1 (40.6-47.7)
1 145 (31.9%) 33.9 (29.5-38.4)
2 36 (7.9%) 31.8 (22.9-40.7)
HS-mGPS .006
0 295 (64.8%) 42.7 (39.3-46.1)
1 135 (29.7%) 35.8 (31.0-40.7)
2 25 (5.5%) 24.5 (17.5-31.5)
CRP/Alb ratio b .001
b0.25 153 (33.6%) 51.7 (47.0-56.3)
≥0.25 302 (66.4%) 34.2 (31.0-37.3)
Tumor-related factors
Tumor location Upper third 178 (39.1%) 32.1 (28.3-36.0) b .001
Middle third 100 (22.0%) 38.8 (32.9-44.7)
Lower third 177 (38.9%) 48.4 (44.0-52.8)
Tumor size (cm) b .001
b3 155 (34.1%) 49.3 (44.5-54.1)
≥3 300 (65.9%) 35.0 (31.9-38.2)
Metastatic lymph node ratio b .001
b0.17 195 (42.9%) 56.6 (52.7-60.4)
≥0.17 260 (57.1%) 27.4 (24.5-30.2)
TNM stage b .001
I 60 (13.2%) 67.1 (61.6-72.5)
II 95 (20.9%) 53.6 (47.9-59.3)
III 300 (65.9%) 30.0 (27.1-32.9)
Kaplan-Meier survival analysis.
340 Prediction of Prognosis of Patients after Gastric Cancer Liu et al. Translational Oncology Vol. 8, No. 4, 2015ratio (NLR), platelet lymphocyte ratio (PLR), and systemic
immune-inflammation index (SII), have been reported to have
prognostic significance in many types of cancer [6–12]. Recently, a
new prognostic index, preoperative C-reactive protein/albumin
(CRP/Alb) ratio, has also been reported as an independent prognostic
marker in hepatocellular carcinoma [13]. However, compared with
other established inflammation-based prognostic scores, the prog-
nostic value of the CRP/Alb ratio in patients with GC is still unclear.
In this study, we performed a large-scale retrospective cohort analysis
to investigate the prognostic value of the preoperative CRP/Alb ratio.
We also compared it with several other markers of the systemic
inflammatory response in patients undergoing curative resection forGC.
Material and Methods
A total of 455 consecutive GC patients who received D2 gastrectomy
with R0 resection at Cancer Center of Sun Yat-sen University
between January 2005 and December 2010 were enrolled. D2
lymphadenectomy was performed following the Japanese Research
Society for Gastric Cancer guidelines [14]. All patients were
histologically confirmed as having stage I to III adenocarcinoma of
the stomach depending on postoperative histological specimen. Our
study complied with the standards of the Declaration of Helsinki and
was approved by the Sun Yat-sen University Cancer Center research
ethics committee. Every patient provided written informed consent
before inclusion.
Data regarding potential prognostic factors were gathered,
including age, sex, preoperative laboratory measurements, postoper-
ative tumor characteristic, and survival times. Blood samples were
obtained within 1 week before surgery to measure the neutrophil,
lymphocyte, and platelet counts; Alb; and CRP. Tumor was staged
according to the seventh edition of the American Joint Committee on
Cancer tumor-nodes-metastasis (TNM) staging [15]. Patients were
excluded if they had infection or inflammatory disease for nearly 1
month, immunity disease, and absent data regarding potential
prognostic factors. Moreover, patients who received neoadjuvant
chemotherapy or radiotherapy were excluded from the study. Patients
were followed up carefully after surgery at 6- to 12-month intervals. A
dynamic computed tomogram and a gastroscope examination were
performed every 6 months. The last follow-up date was April 30,
2014. Overall survival (OS) was calculated from the date of surgery to
the date of death or last follow-up.
Based on previous studies, preoperative body weight loss was defined
as “no, or limited” (≤10%) or “severe” (N10%), and body mass index
(BMI) was defined according to the following categories: b18.5 kg/m2,
≥18.5 to b23 kg/m2, ≥23 to b25.0 kg/m2, or ≥25.0 kg/m2 [16,17].
The NLR and PLR were defined as the absolute neutrophil count and
platelet count divided by the absolute lymphocyte count [18]. The SII
was calculated as follows: SII = P × N/L, where P, N, and L were the
preoperative absolute platelet, neutrophil, and lymphocyte counts,
respectively [9]. The GPS was calculated by CRP and Alb using
standard thresholds (N10 mg/l for CRP and b35 g/l for Alb). Patients
with both a CRP level N10 mg/l and an Alb level b35 g/l were
categorized as having a score of 2. Patients with only one of these
abnormalities were categorized as having a score of 1. Patients with
neither of these abnormalities were categorized as having a score of 0
[19]. The mGPS was determined as previously described [12]. Patients
with an elevated CRP level (N0.5 mg/dl) and hypoalbuminemia
(b3.8 g/dl) were assigned an mGPS of 2, those with only one
abnormality were assigned an mGPS of 1, and those with neither of
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Figure 1.Overall survival based on the preoperative CRP/Alb ratio. Overall survival based on the preoperative CRP/Alb ratio in patients with
stage I to III (A), stage I (B), stage II (C), and stage III (D) GC, respectively.
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determined as follows: patients with an elevatedCRP level (N0.3mg/dl)
and hypoalbuminemia (b3.5 mg/dl) were assigned an HS-mGPS of 2,
those with an abnormality in the CRP level were assigned anHS-mGPS
of 1, and those with neither abnormality were assigned anHS-mGPS of
0 [11]. The CRP/Alb ratio was defined as the serum CRP level divided
by the serum Alb level [20].
Statistical Analysis
Descriptive statistics of patient characteristics were presented as mean
and 95% confidence intervals (CIs). Comparisons between groups
were performed using the χ2 test for categorical variables. If
continuous variable was proven for the assumption of linearity in
the logit, the variable was categorized by generating receiver operating
characteristics (ROC) curve to identify the optimal cutoff value.
Survival analysis and curves were performed according to the
Kaplan-Meier method and compared by the log-rank test. A Cox
proportional-hazard model for multivariable analysis was applied for
variables that proved to be significant in the univariate analysis. Ifvariables were significantly associated with other variables, they were
excluded from the final multivariable analysis. Multivariate P values
were used to characterize the independence and significance of these
factors. The discriminatory ability of the factors to predict OS was
assessed using the area under the curve (AUC).
Statistical analyses were performed using IBM SPSS 19.0 software
(IBM Corporation, Armonk, NY). Differences at P b .05 were
considered to be significant in all statistical analyses.
Results
The clinicopathological characteristics of 455 GC patients and their
association with OS were summarized in Table 1. The median age of
the patients was 59 years (range, 19-86). Overall, 314 (69%) cases
were males and 141 (31%) were females. The median follow-up
period was 25 months (range, 1-76). There were 268 (58.9%) cases
confirmed dead, and 187 (41.1%) were alive at last follow-up.
Based on previous studies, the accepted optimal cutoff value was
determined for some variables, including preoperative body weight
loss, BMI, neutrophil, lymphocyte, and platelet counts [16,17,21,22].
Table 2. Univariate and Multivariate Analyses of OS
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
Patient-related factors
Sex 0.983 (0.757-1.276) .896
Male
Female
Age (years) 1.461 (1.149-1.856) .002 1.447 (1.130-1.853) .003
b60
≥60
Preoperative body weight loss 1.533 (1.301-1.806) b .001 1.324 (1.116-1.571) .001
No
Limited
Severe
BMI (kg/m2) 0.888 (0.777-1.016) .083
b18.5
18.5 ≤ b23.0
23.0 ≤ b25.0
25.0≤
Neutrophils (×109/L) 1.826 (1.241-2.686) .002
b7.5
≥7.5
Lymphocytes (×109/L) 1.183 (0.713-1.960) .515
b3
≥3
Platelet (×109/L) 1.165 (0.759-1.787) .484
b400
≥400
CRP (mg/L) 1.632 (1.193-2.232) .002
≤10
N10
Alb (g/L) 0.507 (0.362-0.710) b .001
b35
≥35
NLR 1.634 (1.285-2.078) b .001 1.095 (0.797-1.503) .576
b2.3
≥2.3
PLR 1.588 (1.227-2.057) b .001 1.204 (0.879-1.650) .247
b180
≥180
SII 1.493 (1.168-1.907) .001 1.036 (0.723-1.485) .846
b660
≥660
GPS 1.634 (1.324-2.015) b .001 1.160 (0.910-1.478) .230
0
1
2
mGPS 1.394 (1.166-1.668) b .001
0
1
2
HS-mGPS 1.361 (1.119-1.654) .002
0
1
2
CRP/Alb ratio 2.225 (1.673-2.960) b .001 1.626 (1.191-2.219) .002
b0.25
≥0.25
Tumor-related factors
Tumor location 0.706 (0.615-0.810) b .001 0.824 (0.713-0.951) .008
Upper third
Middle third
Lower third
Tumor size (cm) 1.900 (1.440-2.507) b .001 0.944 (0.698-1.277) .710
b3
≥3
Metastatic lymph node ratio 4.011 (3.021-5.325) b .001 2.511 (1.715-3.676) b .001
b0.17
≥0.17
TNM stage 2.979 (2.317-3.831) b .001 1.608 (1.138-2.273) .007
I
II
III
342 Prediction of Prognosis of Patients after Gastric Cancer Liu et al. Translational Oncology Vol. 8, No. 4, 2015Besides the variables, ROC curve analysis was used to determine the
optimal cutoff value for others. All the optimal cutoff values for
variables were shown in Table 1. The optimal cutoff value for the
CRP/Alb ratio was 0.025 for the OS. The sensitivity and specificity
were 76.8% and 48.1%, respectively. According to the cutoff level,
patients were divided into two groups (≤0.025, n = 153; N0.025, n =
402). The 1-, 3-, and 5-year OS rates in patients with a CRP/Alb ratio
≤0.025 were 88.3%, 60.7%, and 54.5%, respectively. The survival
rates were significantly higher than those in patients with a CRP/Alb
ratio N0.025, which were 76.9%, 32.6%, and 26.9%, respectively
(P b .001; Figure 1A). In addition, when stratified by TNM stage, the
prognostic significance of CRP/Alb ratio was still maintained in stage I
to III (P = .009, P = .020, and P b .001, respectively; Figure 1, B–D).
A low CRP/Alb ratio was associated with longer median OS in stage I
(72.0 vs 59.6 months), stage II (62.9 vs 47.9 months), and stage III
(38.6 vs 26.4 months), respectively.
The relationship between the CRP/Alb ratio and clinicopathologic
characteristics in GC patients was shown in Table 3. Patients with an
elevated CRP/Alb ratio were more likely found in males (P = .005)
and were associated with age ≥60 years (P b .001), higher neutrophil
counts (P = .040), higher platelet counts (P = .001), elevated NLR
(P b .001), elevated PLR (P b .001), elevated SII (P b .001), higher
GPS score (P b .001), higher mGPS score (P b .001), higher
HS-mGPS score (P b .001), tumor location (upper third) (P = .013),
larger tumor size (P b .001), elevated metastatic lymph node ratio (P =
.005), and higher TNM stage (P b .001).
The results of the univariate andmultivariate analysis were shown in
Table 2. After excluding the related variables, the significant variables
(age, tumor location, metastatic lymph node ratio, tumor size, TNM
stage, NLR, PLR, SII, GPS, and CRP/Alb ratio) were tested in the
multivariate analysis. The multivariate analysis indicated that the age
[hazard ratio (HR): 1.447; 95% CI: 1.130-1.853; P = .003],
preoperative body weight loss (HR: 1.324; 95% CI: 1.116-1.571;
P = .001), CRP/Alb ratio (HR: 1.626; 95% CI: 1.191-2.219; P =
.002), tumor location (HR: 0.824; 95% CI: 0.713-0.951; P = .008),
metastatic lymph node ratio (HR: 2.511; 95% CI: 1.715-3.676; P b
.001), and seventh TNM stage (American Joint Committee on
Cancer) (HR: 1.608; 95% CI: 1.138-2.273; P = .007) were
independent prognostic factors for OS. When GPS was replaced by
mGPS and HS-mGPS, respectively, the results of multivariate analysis
did not change significantly (Supplement Table 1).
As CRP/Alb ratio was significantly associated with other variables
(age, tumor location, metastatic lymph node ratio, and seventh TNM
stage), subgroup analyses were further performed to evaluate the
prognostic value of CRP/Alb ratio more comprehensively. Of note,
the prognostic significance was still maintained when stratified by age
(b60: P b .001; ≥60: P b .001), tumor location (upper third: P =
.001; middle third: P = .004; lower third: P = .007), and metastatic
lymph node ratio (b0.17: P b .001; ≥ 0.17: P b .001).
Considering correlations among the markers of the systemic
inflammatory response, we constructed ROC curves to further assess
their discrimination ability (Figure 2). The discrimination ability of
the CRP/Alb ratio, as assessed by AUC, was 0.625 (95% CI:
0.572-0.678; P b .001), which was higher than that of other markers
(Table 4).
Discussion
It is well known that the systemic inflammatory response plays an
important role in carcinogenesis and tumor progression [23,24].
Table 3. Relationship between the CRP/Alb Ratio and Clinicopathologic Characteristics
CRP/Alb Ratio b 0.25 CRP/Alb Ratio ≥ 0.25 P Value
(n = 153) (n = 302)
Patient-related factors
Sex .005
Male 93 222
Female 60 80
Age (years) b .001
b60 103 150
≥60 50 152
Preoperative body weight loss .363
No 81 139
Limited 53 117
Severe 19 46
BMI (kg/m2) .315
b18.5 19 52
18.5 ≤ b23.0 81 142
23.0 ≤ b25.0 33 57
25.0≤ 20 51
Neutrophils (×109/L) .040
b7.5 146 271
≥7.5 × 109/L 7 31
Lymphocytes (×109/L) .688
b3 144 287
≥3 9 15
Platelet (×109/L) .001
b400 149 267
≥400 4 35
NLR b .001
b2.3 118 151
≥2.3 35 151
PLR b .001
b180 130 206
b180 23 96
SII b .001
b660 121 182
b660 32 120
GPS b .001
0 148 201
1 4 88
2 0 13
mGPS b .001
0 133 141
1 20 125
2 0 36
HS-mGPS b .001
0 153 142
1 0 135
2 0 25
Tumor-related factors
Tumor location .013
Upper third 48 130
Middle third 32 68
Lower third 73 104
Tumor size (cm) b .001
b3 78 78
≥3 75 224
Metastatic lymph node ratio .005
b0.17 80 115
≥0.17 173 187
TNM stage b .001
I 34 27
II 34 60
III 85 215
Figure 2. The predictive ability of the seven inflammation-based
prognostic scores was compared by ROC curves.
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inflammatory microenvironment, inflammatory cells are powerful
tumor promoters [25,26]. Inflammatory responses should also be
thought of as antitumor, but cancer patients are often defective in
inflammatory responses. To date, although the prognostic value of
common inflammation-based prognostic scores, including the GPS,
mGPS, HS-mGPS, NLR, PLR, SII, and CRP/Alb ratio, has beengiven great concern, the mechanisms underlying the relationship
between inflammation and cancer survival have not been elucidated
completely. It may be associated with malnutrition, immune
dysfunction, upregulation of growth factors, angiogenesis, etc.
[27,28]. In recent years, studies have demonstrated that several
important inflammation-based prognostic scores are associated with
various cancer survival outcomes [6–10].
Serum CRP, an acute-phase protein, is produced in hepatocytes,
predominantly under the control of IL-6. It was shown to be very
sensitive prognosis indicator of inflammation in a variety of primary
malignancies, including GC [29–31]. On the other hand, low serum
Alb levels, as a state of malnutrition, have also been considered to be
associated with various cancer survival outcomes, for example,
gastrointestinal, colorectal, lung, and ovarian cancer [32–35].
Furthermore, we can speculate that CRP/Alb ratio, which is based
on both elevated serum CRP concentrations and hypoalbuminemia,
may enable a better appreciation of the outcome of the malignancy. In
fact, Akiyoshi et al. have proved that the CRP/Alb ratio is an
independent prognostic marker in hepatocellular carcinoma [13].
Currently, we first investigate the prognostic significance of these
markers in patients with GC. Of the inflammation-based prognostic
scores, only the CRP/Alb ratio was significantly associated with OS
and had prognostic value independent of TNM stage. More
importantly, we found that its prognostic significance was substan-
tially stable in stage I to III patients undergoing curative resection for
GC. In hepatocellular carcinoma, Akiyoshi et al. also found that an
elevated CRP/Alb ratio was associated with a higher Cancer of the
Liver Italian Program score, Barcelona Clinic Liver Cancer stage, and
Child-Pugh grade. The novel inflammation-based prognostic score
had comparable prognostic ability to other inflammation-based
prognostic scores. They demonstrated that an elevated CRP/Alb
ratio was significantly parallel to tumor progression. Obviously, their
conclusion was consistent with our study [13]. Moreover, we further
explored the association between CRP/Alb ratio and nutritional status.
We found that it was not significantly associated with preoperative
Table 4. Comparison of the AUCs for the Seven Inflammation-Based Prognostic Scores
AUC 95% CI P Value
CRP/Alb ratio 0.625 (0.572-0.678) b .001
NLR 0.594 (0.541-0.646) .001
PLR 0.564 (0.511-0.617) .021
SII 0.571 (0.518-0.624) .010
GPS 0.581 (0.528-0.633) .003
mGPS 0.576 (0.523-0.629) .006
HS-mGPS 0.543 (0.489-0.596) .012
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inflammation but also nutritional status of cancer patients. The data
suggested, in terms of CRP/Alb ratio, that systemic inflammatory
response exerted more potent prognostic effect than nutritional status.
In addition, a study fromCrumley et al. demonstrated that the relation
between hypoalbuminemia and poor outcome was secondary to that
of the systemic inflammatory response, which might also explain part
of the reason [32].
In our study, themultivariate analysis revealed that only theCRP/Alb
ratio, rather than other inflammation-based prognostic scores, was
independently associated with OS. Considering that preoperative
systemic inflammationmight be associated with postoperative infection
that led to poor clinical outcome, we rechecked follow-up data to
further explore whether CRP/Alb ratio adversely affected postoperative
short-term survival. We found that 25 cases died within half a year after
surgery and that none of them died of postoperative infection.
Therefore, CRP/Alb ratio was considered ideal to evaluate prognosis in
GC. More importantly, we found that the prognostic significance,
regardless of TNM stage, was substantially stable. Thismay be useful for
postoperative evaluation of recurrence after curative surgery, especially
in early-stage patients in whom tumor relapse is difficult to predict.
To further evaluate the discrimination ability of the inflamma-
tion-based prognostic scores, ROC curves were performed to
compare the AUC value. The CRP/Alb ratio had a higher AUC
value than other markers (0.625; P b .001). A study from Xu et al.
indicated that the GPS was superior to the NLR and PLR and was
associated with OS in patients undergoing potential curative resection
for stage III GC [36]. Takeno et al. revealed that the HS-mGPS was a
superior prognostic predictor compared with the mGPS in patients
with GC [11]. Hu et al. also showed that the SII could be a more
objective index than the NLR and PLR in hepatocellular carcinoma
[9]. As far as we know, this is the first to include the SII in GC. Our
study proved that the CRP/Alb ratio, in terms of its prognostic ability,
was superior to other inflammation-based prognostic scores,
including the GPS, mGPS, HS-mGPS, NLR, PLR, and SII.
Although the GPS, mGPS, and HS-mGPS use the same variables
to estimate the scores, they may have the potential for underestima-
tion (a lower CRP level) or overestimation (a lower Alb level) in
patients with GC. However, the CRP/Alb ratio reduces these
potential by using the ratio of the CRP and Alb, which may be
superior to them in GC.
It is worth noting that our findings may have important value in
the therapy of GC. With an elevated CRP/Alb ratio, early-stage
patients may need closer follow-up, and local advanced patients may
require more aggressive adjuvant chemotherapy or additional active
therapy. In addition, patients with an elevated CRP/Alb ratio may
benefit from anti-inflammatory therapy or nutritional support
[37–39]. Future studies, especially prospective multicenter clinical
trials, are warranted as validation studies.We acknowledge several potential limitations in present study.
First, it was a retrospective, single-institution, and small-sample-size
study. However, the surgical procedures (R0 resection plus D2
lymphadenectomy), laboratory examinations, and follow-up were
uniform throughout the entire study period. Second, different
postoperative therapy might induce confounding. Third, we lacked
the data of disease-free survival, although OS was the standard
indicator for cancer prognosis study.
Conclusions
To our knowledge, we first demonstrate that preoperative CRP/Alb
ratio is an independent prognostic marker in patients after curative
resection for GC. Moreover, its prognostic ability is superior to other
inflammation-based prognostic scores. Due to its simplicity,
cheapness, and availability, it is of important significance to help
clinicians identify the high-risk patients and enable postoperative
targeted rational therapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.06.006.
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